Axon Enterprise INC Stock
€385.30
Your prediction
Financial data and news for Axon
sharewise wants to provide you with the best news and tools for Axon, so we directly link to the best financial data sources.
Financials
News
Axon Enterprise Touts AI, Global Markets and Counter-Drone Demand as Growth Engines
Key Points
- Interested in Axon Enterprise, Inc? Here are five stocks we like better.
- Axon sees growth across multiple fronts including U.S. public safety, international markets, enterprise
Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
Key Points
- Interested in Unusual Machines, Inc.? Here are five stocks we like better.
- A Wall Street Journal report on the Pentagon's $1.1 billion Drone Dominance program sent drone-related stocks
Axon Enterprise Sees AI, Counter-Drone Demand Fueling Next Growth Wave
Key Points
- Interested in Axon Enterprise, Inc? Here are five stocks we like better.
- Counter-drone demand is accelerating across government, enterprise and international markets, with Axon’s
Axon Enterprise Touts AI, Drone Growth in Push to Be Public Safety’s Operating System
Key Points
- Interested in Axon Enterprise, Inc? Here are five stocks we like better.
- Axon is broadening beyond TASERs into a public safety “operating system,” with growth spanning body cameras
Axon Surged After Earnings and Is Still Down Over 50% From Highs
After getting beaten down for the better part of a year, Axon Enterprise (NASDAQ: AXON) scored a big win after its last earnings report. Shares surged by nearly 11% following the firm’s May
3 Obscure Sectors Where Institutions Are Quietly Loading Up on Shares
Even when the broader market pulls back, money doesn't stop moving. It just moves somewhere most retail investors aren't looking. While geopolitical tension and a months-long software selloff
Axon Got Caught in the SaaS Crash—Its Earnings Say That Was a Mistake
After getting battered in the second half of 2025 and in early 2026, shares of defense company Axon Enterprise (NASDAQ: AXON) just roared back to life. After reporting its Q4 financial results
Is AppLovin the Most Misunderstood AI Stock on the Market?
AppLovin (NASDAQ: APP) has shifted from a gaming-linked ad company into a high-margin AI software platform. Axon 2, the sale of its gaming business, and the push into e-commerce could create a
Could This AdTech Stock Be One of AI's Most Underrated Winners?
AppLovin (NASDAQ: APP) has shifted from a mobile gaming story into a focused AI advertising platform built around Axon, self-service tools, and e-commerce expansion. The growth story looks powerful,
Is AppLovin Stock a Buy as Revenue Continues to Surge?
Outside of the infrastructure space, one of the biggest artificial intelligence (AI) winners has been AppLovin (NASDAQ: APP). The adtech platform has driven tremendous growth since the introduction
2 Factors Dragging Down Axon Enterprise Stock: Should You Buy the Dip?
Shares of Axon Enterprise (NASDAQ: AXON) have been trending lower since late 2025, and have dropped by around 30% so far this year alone. But why has this growth stock fallen into such a slump?
Buy 1 Artificial Intelligence (AI) Stock With More Upside Than Palantir, According to Wall Street Analysts
Palantir Technologies (NASDAQ: PLTR) plays an increasingly important role in the artificial intelligence value chain, and most Wall Street analysts consider the stock undervalued at $143 per share
This AI Stock Is Up 2,000% in 10 Years. It Could Still Soar 103%, Says a Wall Street Analyst (Hint: Not Nvidia or Palantir)
Axon Enterprise (NASDAQ: AXON) shares have advanced 2,000% over the past decade. But every Wall Street analyst covering the company thinks the stock is deeply undervalued at its current price of
Why Axon Stock Bounced Back After Falling 10% Yesterday
Shares of Axon Enterprise (NASDAQ: AXON), the maker of TASER electrical weapons, body cameras, and related software, were moving higher today, one day after the stock plunged 10%.
There was no clear
Axon Stock Plunged on Tuesday. Is This a Buying Opportunity?
Axon Enterprise (NASDAQ: AXON) hit a 18-month-low on Tuesday, though there wasn't any obvious news out on the law enforcement technology leader.
The stock closed down 9.7% and was down more than 12%
2 Tech Stocks That Could Help Make You a Fortune
Building wealth in the stock market is fairly simple if you maintain a long-term mindset and focus on stocks of competitively positioned businesses. Investing in innovative companies with
Wall Street Thinks AppLovin Stock Is a Buy. Here's Why I Don't.
Wall Street loves AppLovin (NASDAQ: APP) right now. The company last month reported 70% revenue growth in 2025, to $5.48 billion, and generated $3.95 billion in free cash flow. Its Q4 revenue hit
Axon Stock Is On Fire, But Here's the Bad News
Axon (NASDAQ: AXON) reported great growth again in the fourth quarter, but that came at the expense of profitability. This isn't a new challenge for Axon, which has compounded revenue growth in
Why Axon Enterprise Stock Was Soaring Today
Shares of Axon Enterprise (NASDAQ: AXON) were surging today after the law enforcement technology company delivered a strong fourth-quarter earnings report, easily beating estimates.
The company also
AppLovin Shares Crash Despite Stellar Growth. Is It Time to Buy the Stock on the Dip?
Despite posting strong fourth-quarter growth and issuing upbeat guidance, shares of AppLovin (NASDAQ: APP) were crashing after the company reported its results. The stock has now lost more than 40%
Why Axon Enterprise Stock Plunged Week
Shares of Axon Enterprise (NASDAQ: AXON), the maker of TASER electrical weapons and body cameras, were taking a dive this week, even though there was no major company-specific news out on it.
The Motley Fool Interviews Axon Enterprise President Josh Isner
Law enforcement technology company Axon Enterprise has produced big returns for investors. Motley Fool analyst Jason Moser recently talked with Axon President Josh Isner about the recent quarter
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported
